Marc B.
- Country
- France
- Department
- Medical oncology
Research Overview
- Efficacy of ONC201 and Everolimus with Radiotherapy in Newly Diagnosed Diffuse Midline Gliomas H3K28M Mutant or EZHIP Positive Patients
- Evaluation of Adjuvant Chemotherapy with Cyclophosphamide, Doxorubicin, and Docetaxel in ER-Positive HER2-Negative Breast Carcinoma in Women Over 70
- Phase 3 Multicenter Open-Label RCT of Duvelisib vs. Gemcitabine or Bendamustine in Relapsed/Refractory Nodal T-Cell Lymphoma with TFH Phenotype
Data & Insights
Has run more than one trial at 28 of 152 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating T-cell lymphomas, with particular expertise in rare subtypes such as nodal T-cell lymphoma with T follicular helper phenotype.
- T-cell Lymphoma Management
- Refractory Blood Cancer Treatment
- Relapsed Lymphoma Therapy
Treatment approaches focus on innovative therapeutic solutions for patients whose conditions have not responded to conventional treatments.
Therapeutic Innovation
The investigator works with novel therapeutic agents including targeted therapies for blood cancers, exploring alternatives to traditional chemotherapy approaches.
- Novel Drug Development
- Alternative Treatment Strategies
- Comparative Treatment Studies
Expertise extends to evaluating treatment efficacy through progression-free survival assessment.
Clinical Assessment
The investigator employs sophisticated methodologies to evaluate treatment response in hematologic malignancies, utilizing independent review processes.
- Treatment Response Evaluation
- Disease Progression Monitoring
- Clinical Outcome Assessment
Focus includes determining therapeutic efficacy in challenging blood cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.